Paola Ghione1, Alison J Moskowitz1, Nadia E K De Paola1, Steven M Horwitz1, Marco Ruella2,3. 1. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu. 3. Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.
Abstract
PURPOSE OF REVIEW: Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia. RECENT FINDINGS: For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists. In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.
PURPOSE OF REVIEW: Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia. RECENT FINDINGS: For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists. In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.
Authors: E Matutes; V Brito-Babapulle; J Swansbury; J Ellis; R Morilla; C Dearden; A Sempere; D Catovsky Journal: Blood Date: 1991-12-15 Impact factor: 22.113
Authors: Josine van Beek; Axel zur Hausen; Sander N Snel; Johannes Berkhof; Elma Klein Kranenbarg; Cornelis J H van de Velde; Adriaan J C van den Brule; Jaap M Middeldorp; Chris J L M Meijer; Elisabeth Bloemena Journal: Am J Surg Pathol Date: 2006-01 Impact factor: 6.394
Authors: H Miles Prince; Youn H Kim; Steven M Horwitz; Reinhard Dummer; Julia Scarisbrick; Pietro Quaglino; Pier Luigi Zinzani; Pascal Wolter; Jose A Sanches; Pablo L Ortiz-Romero; Oleg E Akilov; Larisa Geskin; Judith Trotman; Kerry Taylor; Stephane Dalle; Michael Weichenthal; Jan Walewski; David Fisher; Brigitte Dréno; Rudolf Stadler; Tatyana Feldman; Timothy M Kuzel; Yinghui Wang; Maria Corinna Palanca-Wessels; Erin Zagadailov; William L Trepicchio; Wenwen Zhang; Hui-Min Lin; Yi Liu; Dirk Huebner; Meredith Little; Sean Whittaker; Madeleine Duvic Journal: Lancet Date: 2017-06-07 Impact factor: 79.321
Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu Journal: N Engl J Med Date: 2017-09-08 Impact factor: 91.245
Authors: Monica Bellei; Francine M Foss; Andrei R Shustov; Steven M Horwitz; Luigi Marcheselli; Won Seog Kim; Maria E Cabrera; Ivan Dlouhy; Arnon Nagler; Ranjana H Advani; Emanuela A Pesce; Young-Hyeh Ko; Virginia Martinez; Silvia Montoto; Carlos Chiattone; Alison Moskowitz; Michele Spina; Irene Biasoli; Martina Manni; Massimo Federico Journal: Haematologica Date: 2018-03-29 Impact factor: 9.941
Authors: Valentina Cordo'; Jordy C G van der Zwet; Kirsten Canté-Barrett; Rob Pieters; Jules P P Meijerink Journal: Blood Cancer Discov Date: 2020-11-24
Authors: Ayse Meric Ovacik; Ji Li; Marie Lemper; Dimitry Danilenko; Nicola Stagg; Mary Mathieu; Diego Ellerman; Vinita Gupta; Navdeep Kalia; Trung Nguy; Vicki Plaks; Clarissa David Johnson; Weiru Wang; Jochen Brumm; Bernard Fine; Teemu Junttila; Kedan Lin; Paul J Carter; Saileta Prabhu; Christoph Spiess; Amrita V Kamath Journal: MAbs Date: 2018-12-17 Impact factor: 5.857